Models of prion disease

Abstract

The present invention provides a novel PrP protein, and nucleic acids encoding this protein, where the PrP protein is characterized in vivo by 1) incomplete glycosylation relative to glycosylation of wild-type PrPC and 2) proper cellular localization, i.e. an ability to be transported to the cell surface. This novel, under-glycosylated PrP, unlike its normal cellular counterpart, can easily be converted into a protease-resistant isoform by incubation with infectious prions. The invention further provides systems for the study of prion disorders and methods of using these systems, e.g. the study of the mechanical processes in progression of prion-mediated disease or the identification of new therapeutic agents for treatment of prion-mediated disorders. In such systems, protease-resistant under-glycosqvated PrP is generated de novo and can be detected by standard immunoblot techniques.

Description

GOVERNMENT RIGHTS [0001] The United States Government may have certain rights in this application pursuant to Grant No. AG10770 awarded by the National Institutes of Health.FIELD OF THE INVENTION [0002] The present invention relates generally to systems for studying neurodegenerative disorders, and in particular to systems for the study of prion-associated disease. BACKGROUND OF THE INVENTION [0003] Perons are infectious pathogens that cause central nervous system spongiform encephalopathies in humans and animals. -Prions are distinct from bacteria, viruses and viroids. The predominant hypothesis at present is that no nucleic acid component is necessary for infectivity of prion protein. Further, a prion which infects one species of animal (e.g., a human) will not readily infect another (e.g., a mouse). [0004] A major step in the study of prions and the diseases that they cause was the discovery and purification of a protein designated prion protein (“PrP”) [Bolton et al., Science 21...

AI Technical Summary

Benefits of technology

Enables rapid infection and symptom development in transgenic animals, facilitating the study of prion disease progression and the identification of therapeutic agents, while providing a humane and cost-effective alternative to traditional animal models.

Problems solved by technology

Although previous Thr to Ala substitutions in the glycosylation sites of PrP resulted in conformational instability, the resulting PrPC molecules displayed an aberrant cellular localization and resulted in a very long prion incubation period when expressed in transgenic mice.

In vitro methods of diagnosing prion disease in a suspected diseased brain, such as detection of the presence of protease-resistant PrP on Western blots, is limited by the sensitivity of the immunological assay.